### PEST AVAILABLE COPY

OTPE 4005

OCT 18 2005

PARADEMARTION

**DRAWINGS** 

1/29

Fig. 1
Inhibition effects of anti-HIV agents of the primary processed matter on the syncytium formation of non-infected cells co-cultured with infected cells




Fig. 1b
Inhibition effects of anti-HIV agents of the present invention on the syncytium formation of non-infected cells co-cultured with infected cells





Fig. 2
Inhibition effects of anti-HIV agents of the primary processed matter on HIV production by PHA-stimulated peripheral blood mononuclear cells that were made to be newly infected.







Fig. 2b
Inhibition effects of anti-HIV agents of the present invention on HIV production by PHA-stimulated peripheral blood mononuclear cells that were made to be newly infected.







Fig. 3

Number of viable cells







Fig. 3b

#### Number of viable cells







Fig. 4

ELISA test for HIV P24 antigen yield







Fig. 4b

ELISA test for HIV P24 antigen yield








Fig. 5
Anti-HIV effects of pretreated PHA-stimulated peripheral blood mononuclear cells with Kabanoanatake

#### A The effects of pretreatment HIV with Kabanoanatake




#### B The effects of target cell pretreatment with Kabanoanatake



\* The anti-HIV agents were prepared in PBS solution at the concentration of 3.5 mg/ml.

Fig. 6

A The effects of pretreatment of target cells with Kabanoanatake



Pretreatment time of target cells with Kabanoanatake (hours)

B The effects of addition of Kabanoanatake in various incubation times after target cells pretreatment with anti-HIV agents for approximately one hour





Fig. 6

A-2 The effects of pretreatment of target cells with Kabanoanatake



Pretreatment time of target cells with Kabanoanatake (hours)

## B-2 The effects of addition of Kabanoanatake in various incubation times after target cells pretreatment with anti-HIV agents for approximately one hour






Fig. 7
Inhibition effects of anti-HIV agents of the primary processed matter on the syncytium formation of non-infected cells co-cultured with infected cells




<sup>\*</sup> The anti-HIV agents were prepared at the concentration of 3.56 mg/ml.

Fig. 7b
Inhibition effects of anti-HIV agents of the present invention on the syncytium formation of non-infected cells co-cultured with infected cells



<sup>\*</sup> The anti-HIV agents were prepared at the concentration of 3.56 mg/ml.

Fig.8






Fig.8b




Fig. 9
Inhibition effects of various Kabanoanatake of the primary processed matter on the syncytium formation of non-infected cells co-cultured with infected cells




Fig. 9b
Inhibition effects of various Kabanoanatake of the present invention on the syncytium formation of non-infected cells co-cultured with infected cells




Fig. 10

#### Report of separation of HIV

July, 18<sup>th</sup>, 1995

Day of receipt of samples: June, 14th, 1995

#### (1) Tissue culture infectious dose (TCID)

Total TCID (/ ml)	0
Cell TCID (/1×10 <sup>6</sup> )	0
Plasma TCID (/ ml)	0
Cytopathic effect	0

#### (2) Anti-HIV antibody in plasma by western blotting methods.

gp160	gp120	p65	p55	p51	gp41-43	p32	p24	p18	p15
(env)	(env)	(pol)	(gag)	(pol)	(env)	(pol)	(gag)	(gag)	(gag)
++	++	++	++	++	++	++	++	++	++

#### (3) Host range index

(Correspondence column) The virus was not isolated.

(Annotation) Also, in a blood test after three months for the same patient, TCID value was excellent (zero).

**Fig. 10b** 

#### Report of separation of HIV

August, 1<sup>st</sup>, 1998

Day of receipt of samples: June, 14th, 1995

#### (1) Tissue culture infectious dose (TCID)


Total TCID (/ ml)	0
Cell TCID $(/1 \times 10^6)$	0
Plasma TCID (/ ml)	0
Cytopathic effect	


#### (2) Anti-HIV antibody in plasma by western blotting methods.


gp160	gp120	p65	p55	p51	gp41-43	p32	p24	p18	p15
(env)	(env)	(pol)	(gag)	(pol)	(env)	(pol)	(gag)	(gag)	(gag)
++	++	++	++	++	++	++	++	++	++


#### (3) Host range index


(Correspondence column) The virus was not isolated.































Fig. 22 The values of perfect HIV inhibition activity (100%) on the 110th day of a liquid culture of Kabanoanatake hyphae, A to E, at the ideal temperature for culture of 25%








Fig. 25
Incident rate of papillomas, using the 2-stage carcinogenesis model with mouse skin (average number per mouse)





Fig. 26

The carcinogenetic promotion suppression effects of Compound 1, using the 2-stage carcinogenesis model with mouse skin (percentage)



# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

#### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
□ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
□ FADED TEXT OR DRAWING
□ BLURRED OR ILLEGIBLE TEXT OR DRAWING
□ SKEWED/SLANTED IMAGES
□ COLOR OR BLACK AND WHITE PHOTOGRAPHS
□ GRAY SCALE DOCUMENTS
□ LINES OR MARKS ON ORIGINAL DOCUMENT
□ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

#### IMAGES ARE BEST AVAILABLE COPY.

OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.